Numis Securities restated their buy rating on shares of Ergomed (LON:ERGO) in a research note issued to investors on Thursday, January 25th. Numis Securities currently has a GBX 300 ($4.14) price objective on the stock.
Separately, N+1 Singer reiterated a corporate rating on shares of Ergomed in a report on Friday, December 15th.
Ergomed (LON ERGO) traded up GBX 3 ($0.04) during midday trading on Thursday, reaching GBX 200 ($2.76). The company had a trading volume of 4,883 shares, compared to its average volume of 54,893. Ergomed has a fifty-two week low of GBX 165 ($2.28) and a fifty-two week high of GBX 225 ($3.11). The firm has a market capitalization of $84.66 and a PE ratio of 20,000.00.
In other news, insider Peter George bought 500,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was acquired at an average cost of GBX 190 ($2.63) per share, with a total value of £950,000 ($1,312,517.27).
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/12/ergomeds-ergo-buy-rating-reaffirmed-at-numis-securities.html.
Ergomed Company Profile
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.
Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.